Research Paper Volume 16, Issue 4 pp 3915—3933
Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma
Figure 9. Drug sensitivity exploration. The distribution of IC50 in (A) Sorafenib. (B) Sunitinib. (C) Saracatinib. (D) Paclitaxel. (E) Dasatinib. (F) Imatinib. (G) Rapamycin. (H) Erlotinib. (I–P) Correlation analysis of ARLs prognostic signature and drug sensitivity (IC50).